Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than clopidogrel and is associated with less interindividual variability. In the PLATO trial, it was found to be superior to clopidogrel with respect to cardiovascular outcomes and total mortality without increasing the risk of bleedings.

More potent and reversible receptor bindings are possible explanation for the superior outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake in tissue level and can induce adenosine triphosphate (ATP) release from human red cells, which both stimulate vasodilation of in red blood cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Ticagrelor Versus Clopidogrel on Microcirculation

NCT02618733

Acute Coronary Syndrome

COMPLETED NA

Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.

NCT01961856

Platelet Reactivity

COMPLETED PHASE3

Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome

NCT01626534

Acute Coronary Syndrome

COMPLETED PHASE3

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

NCT02123004

ST-Segment Elevation Myocardial Infarction

UNKNOWN PHASE4

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

NCT02319941

Acute Coronary Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-ST Segment Elevation Myocardial Infarction ST Segment Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clopidogrel

Clopidogrel 600mg loading

Group Type EXPERIMENTAL

Clopidogrel

Intervention Type DRUG

Clopidogrel 600mg loading

Ticagrelor

Ticagrelor 180mg loading

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

Ticagrelor 180mg loading

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel

Clopidogrel 600mg loading

Intervention Type DRUG

Ticagrelor

Ticagrelor 180mg loading

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and Females
* between the ages of 18 and 75 years
* STEMI patients treated with percutaneous coronary intervention
* Able to provide informed consent

Exclusion Criteria

* History of stroke or transient ischemic attack
* Platelet count \< 100 000/μL
* Known Bleeding Diathesis
* Hematocrit \<30% or \>52%
* Severe Liver Dysfunction
* Renal Insufficiency (Creatinine Clearance \< 30ml/min)
* Pregnant females
* Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No